Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast by unknown
RESEARCH ARTICLE Open Access
Clinicopathological implications of Tiam1
overexpression in invasive ductal
carcinoma of the breast
Zhenling Li1,2†, Qixiang Liu2†, Junjie Piao1, Fenjian Hua2, Jing Wang2, Guang Jin1, Zhenhua Lin1* and Yan Zhang2*
Abstract
Background: T-lymphoma invasion and metastasis-inducing protein 1 (Tiam1) has been implicated in tumor
occurrence and progression. Recent studies have shown that high expression levels of Tiam1 protein appear to be
associated with the progression of numerous human tumors. This study attempted to explore the role of Tiam1
protein in tumor progression and the prognostic evaluation of breast cancer.
Methods: The localization of the Tiam1 protein was determined in the MDA-MB-231 breast cancer cell line using
immunofluorescence (IF) staining. In addition, a total of 283 breast tissue samples, including 153 breast cancer
tissues, 67 ductal carcinoma in situ (DCIS) and 63 adjacent non-tumor breast tissues, were analyzed by
immunohistochemical (IHC) staining of the Tiam1 protein. The correlation between Tiam1 expression and
clinicopathological characteristics was evaluated by Chi-square test and Fisher’s exact tests. Disease-free survival
(DFS) and 10-year overall survival (OS) rates were calculated by the Kaplan-Meier method. Additionally, univariate
and multivariate analyses were performed by the Cox proportional hazards regression models.
Results: Tiam1 protein showed a mainly cytoplasmic staining pattern in breast cancer cells; however, nuclear
staining was also observed. Tiam1 protein expression was significantly higher in breast cancers (42.5 %, 65/153) and
DCIS (40.3 %, 27/67) than in adjacent non-tumor tissues (12.7 %, 8/63). In addition, Tiam1 associated with tumor
stage and Ki-67 expression, but negatively correlated with receptor tyrosine-protein kinase erbB-2 (Her2) expression.
Moreover, survival analyses showed that DFS and 10-year OS rates were significantly lower in breast cancer patients
with high Tiam1 expression than those with low Tiam1 expression. Univariate analysis suggested that molecular
types, clinical stage, Her2 expression levels and Tiam1 expression levels were also significantly associated with DFS
and 10-year OS rates of breast cancer patients. Furthermore, multivariate analysis suggested that Tiam1 expression
is a significant independent prognostic factor along with tumor stage in patients with breast cancer.
Conclusions: Tiam1 expression is frequently up-regulated in breast cancer. Tiam1 expression correlated with
clinicopathological parameters, suggesting that it may be a useful prognostic biomarker and potential therapeutic
target for patients with breast cancer.
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Background
Breast cancer is one of the most common tumors in
women worldwide, accounting for approximately 29 %
of all new cancer cases among women, and it is the most
common cause of cancer death in women. Specifically,
more than 226,870 new cases and 39,510 deaths are re-
ported each year worldwide [1]. Ductal carcinoma in situ
(DCIS) is defined as local disease involving the prolifera-
tion of abnormal epithelial cells that have not crossed
the basement membrane and invaded the stroma, and is
considered to be a non-obligate precursor to invasive
breast cancer [2]. Moreover, invasive breast cancer in-
cludes at least four major molecular subtypes, which dif-
fer by their expression of estrogen receptor alpha (ER),
progesterone receptor (PR), receptor tyrosine-protein
kinase erbB-2 (Her2), and the proliferative status of the
tumor [3, 4]. The levels of ER, PR and Her2 expression
are closely related to breast cancer, and have been used
for predicting the outcomes and response to breast can-
cer therapy. Currently, although therapeutic strategies
have improved, existing prognosis factors have failed to
provide the necessary precision needed for making
therapeutic decisions.
T-lymphoma invasion and metastasis-inducing factor
1 (Tiam1) was first identified as an invasion and
metastasis-related gene by Habets et al. [5] in mice with
aggressive T-cell lymphoma. Tiam1 is a guanine nucleo-
tide exchange factor (GEF) and regulates guanosine tri-
phosphatase to facilitate the exchange of guanosine
diphosphate for guanosine triphosphate. Tiam1 expres-
sion plays an important role in tumor progression and
metastasis by activating Rho-like GTPases, specifically
the Tiam1-Rac pathway, which participates in cell migra-
tion, invasion and metastasis [6, 7]. Moreover, the in-
creased expression of Tiam1 has been reported in a
variety of tumor types, such as colorectal carcinoma [8],
hepatocellular carcinoma [9], prostate carcinoma [10],
lung carcinoma [11] and squamous-cell carcinoma of
the head and neck [12]. Overexpression of Tiam1 pro-
tein participates in many processes underpinning tumor
progression [7, 13], including apoptosis, lymphangiogen-
esis, invasion and migration. All these findings indicate
that Tiam1 expression might be a new and independent
predictor of prognosis in various tumors, and Tiam1
may be a potential target for tumor therapy. However,
there are relatively few published reports evaluating the
role of Tiam1 protein expression in breast cancer.
Therefore, in this study, a total of 153 breast cancer
samples, 67 DCIS and 63 adjacent non-tumor breast tis-
sues were evaluated for the expression of Tiam1 by im-
munohistochemical (IHC) staining. Herein, we report
that the expression of Tiam1 is important in the tumori-




This research complied with the Helsinki Declaration
and was approved by the Human Ethics Committee and
the Research Ethics Committee of Yanbian University
Medical College. Patients were informed that the
resected specimens were stored by the hospital and po-
tentially used for scientific research, and that their priv-
acy would be maintained. Follow-up survival data were
collected retrospectively through medical record
analyses.
Clinical samples
Total 283 tissue samples were used for this study, in-
cluding 153 were breast cancer samples, 67 DCIS and 63
adjacent non-tumor breast tissues. All of these tissues
were collected from Shanghai Outdo Biotech Co. Ltd.
(Outdo Biotech) and Tissue Bank of Yanbian University
Medical College. All tissues were routinely fixed in 10 %
buffered formalin and embedded in paraffin blocks. The
study protocol was approved by the institutional review
board of Yanbian University Medical College. The patho-
logical parameters, including age, menopausal status,
molecular type, tumor size, LN metastasis, ER expres-
sion, PR expression, Her2 expression and Ki-67 expres-
sion were carefully reviewed in all 153 breast cancer
cases. All cases were confirmed with breast cancer by
pathological examination. Clinicopathological classifica-
tion and staging were assessed according to the American
Joint Committee on Cancer (AJCC) criteria. Clinical infor-
mation of the samples is summarized in Table 2.
Cell culture
MDA-MB-231 human breast cancer cells were supplied
by the Cancer Research Center of Yanbian University.
The cells were plated onto cell culture dishes, and cul-
tured in 10 % fetal bovine serum L-15 medium. And
then, the cells maintained at 37 °C in a humidified incu-
bator in an atmosphere of 5 % CO2.
Immunofluorescence (IF) staining of the Tiam1 protein in
MDA-MB-231 breast cancer cells
The breast cancer cell line, MDA-MB-231, was grown
on coverslips to 70 % confluence and then the cells were
fixed in 4 % paraformaldehyde in PBS for 10 min at RT,
and permeabilized with 0.5 % TritonX-100 for 10 min.
Blocking was performed with 3 % bovine serum albumin
fraction V (A8020, Solarbio, Beijing, China) for 1 h at
RT. After washing with phosphate-buffered saline (PBS),
cells were incubated with anti-rabbit Tiam1 (1:500,
Santa Cruz Biotechnology) at 4 °C overnight, followed
by incubation with Alexa Fluor® 488 goat anti-rabbit IgG
(H + C) (A11008, Invitrogen, USA) respectively, for 1 h
at RT. After washing with PBS, cells were counterstained
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with 4’,6-diamidino-2-phenylindole (DAPI) (C1006,
Beyotime, Shanghai, China) and the coverslips were
mounted with Antifade Mounting Medium (P0126,
Beyotime, Shanghai, China). Finally, the immunofluores-
cence signals were visualized and recorded by Leica
SP5II confocal microscope.
Immunohistochemistry (IHC) for Tiam1 protein in
paraffin-embedded tissues
IHC analysis was performed using the DAKO LSAB kit
(DAKO A/S, Glostrup, Denmark). Briefly, to eliminate
endogenous peroxidase activity, 4 μm thick tissue sec-
tions were deparaffinized, rehydrated and incubated with
3 % H2O2 in methanol for 15 min at RT. The antigen
was retrieved at 95 °C for 20 min by placing the slides in
0.01 M sodium citrate buffer (pH 6.0). The slides were
then incubated with Tiam1 antibody (1:600, Santa Cruz
Biotechnology, USA) at 4 °C overnight. After incubation
with biotinylated secondary antibody at RT for 30 min,
the slides were incubated with streptavidin-peroxidase
complex at RT for 30 min. IHC staining was developed
by using 3,3′-diaminobenzidine, and Mayer’s hematoxylin
was used for counterstaining. In addition, the positive tis-
sue sections were processed with omitting of the primary
antibody as negative controls.
Evaluation of IHC staining
All specimens were examined by two investigators (Jin T
& Lin Z) who did not possess knowledge of the clinical
data. In case of discrepancies, a final score was estab-
lished by reassessment on a double-headed microscope.
Briefly, the IHC staining for Tiam1 was semi-
quantitatively scored as ‘−’ (negative, no or less than 5 %
positive cells), ‘+’ (6–25 % positive cells), ‘++’ (26–75 %
positive cells), and ‘+++’ (more than 75 % positive cells,
considered as strongly positive).
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware program for windows, version 17.0 (SPSS, Inc.,
Chicago, IL, USA), and the JMP software program for
Mac, version 10.0.0 (SAS Institute Inc., Cary, NC, USA).
Correlation between Tiam1 expression and clinicopatho-
logical characteristics were evaluated by Chi-square test
and Fisher’s exact tests. The survival rates after tumor
removal were calculated by the Kaplan-Meier method,
and differences in survival curves were analyzed by the
Log-rank tests. Multivariate survival analysis was per-
formed on all the significant characteristics measured by
univariate survival analysis through the Cox proportional
hazard regression model. P-values less than 0.05 were
considered statistically significant.
Results
Tiam1 protein expression is increased in breast cancers
To determine the expression levels of Tiam1 in breast
cancer patients, we performed IHC. The staining pattern
of Tiam1 protein was primarily cytoplasmicin breast
cancers, but nuclear staining was also observed (Fig. 1).
The proportion of samples with high Tiam1 expression
was 76.5 % (117/153) in breast cancer; it was signifi-
cantly higher than in DCIS (51.1 %, 35/67) or adjacent
non-tumor tissues (28.6 %, 18/63). Similarly, the propor-
tion of samples with strongly positive Tiam1 expression
was 42.5 % (65/153) in breast cancer and40.3 % (27/67)
in DCIS, which were significantly higher than that of
Fig. 1 IHC staining of Tiam1 protein in breast cancer tissues. a Lack of Tiam1 protein staining in normal breast tissues. b Tiam1 protein was
showed weakly positive in DCIS tissues. c Diffuse and strong positive expression of Tiam1 protein staining in breast cancer cells with LN
metastasis (Luminal B). d Tiam1 was weakly positive in breast cancers with LN metastasis (Luminal B). e Lack of Tiam1 protein staining in breast
cancers without metastasis (triple negative). f Tiam1 protein staining localized some nuclear staining was also observed in the metastatic breast
cancers with lymphatic vessel invasion (triple negative). (Original magnification, A-F: ×200)
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adjacent non-tumor tissues (12.7 %, 8/63) (P < 0.01,
respectively) (Table 1).
The subcellular localization of Tiam1 protein was fur-
ther explored by performing IF staining for Tiam1 pro-
tein in MDA-MB-231 breast cancer cells. The staining
results clearly showed that Tiam1 protein is mainly lo-
cated in the cytoplasm of MDA-MB-231 breast cancer
cells, while some nuclear staining was also observed
(Fig. 2).
Clinicopathological significance of Tiam1 overexpression
in patients with breast cancer
To evaluate the role of Tiam1 protein in breast cancer
progression, the relationship between the overexpression
of Tiam1 protein and the clinicopathological parameters
of patients were analyzed. According to the clinical pa-
rameters of the breast cancer patients listed in Table 2,
Tiam1 overexpression was not related to patient age,
menopausal status, molecular type, lymph node (LN)
metastasis, ER or PR expression levels (P > 0.05, respect-
ively). However, for tumor stage, we found strongly posi-
tive immunostaining (56.5 %, 39/69) in breast cancer
patients with T2-T3 (>5.0 cm) tumor size, but only 31 %
(26/84) in cases with T0-T1 (≤5.0 cm) tumor size (P =
0.002). In addition, Tiam1 was significantly higher in
breast cancers with high Ki-67 expression (50.0 %, 51/
102) than in cases with low Ki-67 expression (27.5 %,
14/51) (P = 0.008). Interestingly, the strongly positive
rate of Tiam1 expression was 47.3 % (53/112) in breast
cancers with HER2 negative expression, but only 29.3 %
(12/41) in case with HER2 positive expression (P =
0.046) (Fig. 3).
Tiam1 overexpression predicts poor survival rates in
patients with breast cancer by the Kaplan-Meier method
To further substantiate the importance of Tiam1 overex-
pression in breast cancer progression, 153 breast cancer
cases were analyzed using the Kaplan-Meier method.
We found that breast cancer patients with high Tiam1
expression had lower DFS and 10-year OS (P = 0.003, re-
spectively) rates than those with low Tiam1 expression
(Fig. 4). Among the 153 breast cancer patients, 84 were
early-stage and 69 were late-stage. In early-stage breast
cancers, patients with low-level Tiam1 expression had
higher DFS and OS rates compared with those with
high-level Tiam1 expression (P = 0.021 and P = 0.043, re-
spectively). Similarly, for patients with late-stage breast
cancer, the expression status of Tiam1 protein was also
correlated with DFS and 10-year OS rates (P = 0.003 and
P = 0.007, respectively) (Fig. 5).
Tiam1 overexpression is an independent prognostic
biomarker in breast cancers by Cox proportional hazards
regression model
Univariate analysis demonstrated that breast cancer pa-
tients with high Tiam1 expression had significantly lower
DFS and 10-year OS rates than those with low Tiam1
expression tumors. Additionally, molecular type, clinical
stage, and HER2 expression levels were also associated
with DFS and 10-year OS rates, when Tiam1 was
expressed (Table 3). These data suggested that Tiam1
could be used as a valuable prognostic factor in breast
cancer. Therefore, multivariate analysis was performed
using the Cox proportional hazards model for all of the
significant variables, which were examined in the univar-
iate survival analysis. We found that tumor stage proved
to be a significant independent prognostic factor for
DFS (HR: 0.567, 95 % CI: 0.413–0.778, P = 0.000) and
10-year OS (HR: 0.585, 95 % CI: 0.425–0.805, P = 0.001)
in patients with breast cancers. Importantly, high Tiam1
expression also emerged as a significant independent
prognostic factor for DFS (HR: 1.470, 95 % CI: 1.056–
2.047, P = 0.022) and 10-year OS (HR: 1.549, 95 % CI:
1.112–2.157, P = 0.010) in patients with breast cancer
(Table 3).
Discussion
Tiam1 was first detected as an invasion and metastasis
gene by Habets et al. [5] and was identified as the spe-
cific GEF for the Rho-like GTPase. It was reported to
participate in tumor progression and metastasis by acti-
vating Rho-like GTPases, specifically the Tiam1-Rac
pathway [6, 7]. The small GTPases of the Rho family
have been recognized as key regulators of signal trans-
duction pathways that regulate the phenotypic cytoskel-
eton changes required for cell spreading, chemotaxis,
and invasion [14]. Rho-like GTPases, in conjunction
with GEFs, act as molecular switches by cycling between
an active GTP-bound state and an inactive GDP-bound
state. Michiels et al. [15] indicated that the Tiam1-Rac
signaling pathway could be involved in the invasion and
metastasis of cancer cells. Furthermore, the Tiam1-Rac
signaling axis is able to cross-talk with other signaling
pathways, such as the c-Jun N-terminal kinase (p38
MAPK) pathway and the extracellular signal-regulated
kinase pathway [16, 17], which may implicate the










− + ++ +++
Breast cancers 153 36 52 41 24 76.5 %** 42.5 %**
DCIS 67 32 8 14 13 51.1 %** 40.3 %**
Adjacent non-tumor 63 45 10 8 0 28.6 % 12.7 %
DCIS ductal carcinoma in situ
Positive rate: percentage of positive cases with + ~+++ staining score
Strongly positive rate: percentage of positive cases with ++ and +++
staining score
** p < 0.01 compared with non-tumor tissues
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Tiam1-Rac pathway in the regulation of gene transcrip-
tion. Additionally, several studies reported the role of
Tiam1 in the promotion of malignant transformation,
tumor proliferation, invasion and metastasis [18–23].
Moreover, Tiam1 has been reported to participate in the
regulation of the tumor microenvironment [24] by pro-
moting the formation of E-cadherin-mediated cell-cell
adhesion.
Accumulating evidence has shown that Tiam1 is
expressed at relatively high levels in a variety of human
malignancies, and a correlation between Tiam1 overex-
pression and several human cancers has been identified.
Engers et al. [10] reported that Tiam1 expression was
strongly increased in prostate cancer and high-grade
prostate intraepithelium neoplasia (HG-PIN) lesions,
compared with adjacent benign epithelium. The authors
further demonstrated that Tiam1 overexpression in
prostate cancer might be an independent prognostic
marker of tumor recurrence. Similarly, Guo et al. [25]
also indicated that the Tiam1-Rac1 axis is involved in pan-
creatic cancer cell proliferation and invasion. Inspired by
these findings, we performed IHC staining of Tiam1 pro-
tein in 153 breast cancer samples, 67 DCIS and 63 adja-
cent non-tumor breast tissues. From our IHC results we
found that Tiam1 is predominately localized in the cyto-
plasm, although some nuclear staining was also observed.
These observations were consistent with the IF staining
results in MDA-MB-231 breast cancer cells. Adam et al.
[14] reported that Tiam1 is mainly located in the cyto-
plasm, and when cells are treated with heregulin-β1Tiam1
is detected in the nucleus. Otsuki et al. [26] also indicated
that the expression of Tiam1 was demonstrated in the nu-
clei of cerebral neuronal cells. These findings are consist-
ent with our observations. We also observed that Tiam1
protein is frequently overexpressed both in breast cancer
and DCIS specimens, at significantly higher levels than
normal breast tissues. DCIS is non-invasive breast cancer,
which can increase the possibility of developing an inva-
sive breast cancer. These results demonstrated that up-
regulation of Tiam1 expression may occur at an early
stage in breast cancer. Consistent with many other re-
ports, Tiam1 may play an important role in tumorigenesis
and malignant progression of breast cancer.
Fig. 2 Immunofluorescence staining of the Tiam1 protein in MDA-MB-231 breast cancer cells. The Tiam1 protein was mainly located in the cytoplasm
of MDA-MB-231 breast cancer cells, and nuclear staining pattern was also observed (red indicates Tiam1 staining, blue indicates DAPI)
Table 2 Correlation between Tiam1 expression and the







≥ 50 84 37 (44.0 %)
< 50 69 28 (40.6 %)
Menopausal status 1.981 0.159
Premenopausal 63 31 (49.2 %)
Postmenopausal 90 34 (37.8 %)
Molecular type 5.142 0.162
Luminal A 39 21 (53.8 %)
Luminal B 46 21 (45.7 %)
TNBC 39 15 (35.9 %)
Her2+ 29 8 (27.6 %)
Tumor stage 10.136 0.002**
T0-T1 84 26 (31.0 %)
T2-T3 69 39 (56.5 %)
LN metastasis 0.364 0.546
Absent 57 26 (45.6 %)
Presence 96 39 (40.6 %)
ER 0.453 0.501
Positive 87 39 (44.8 %)
Negative 66 26 (39.4 %)
PR 0.489 0.484
Positive 78 31 (39.7 %)
Negative 75 34 (45.3 %)
Her2 4.003 0.046*
Positive 41 12 (29.3 %)
Negative 112 53 (47.3 %)
Ki-67 7.075 0.008**
Positive 102 51 (50.0 %)
Negative 51 14 (27.5 %)
* p < 0.05, ** p < 0.01
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According to the molecular gene expression profiles of
breast cancer biopsies, patients are classified into the fol-
lowing subtypes: ER positive (Luminal A and B) and ER
negative (triple negative and HER2 positive) groups. Clas-
sification into the different subtypes can change tumor
prognosis and responses to therapy. In addition, HER2
positive tumors are traditionally associated with poor
prognosis. In fact, Yan et al. [27] also reported that in
addition to ER status, HER2 status might play an import-
ant role in prognosis prediction. In our study, the expres-
sion of Tiam1 protein was significantly higher in breast
cancers with low HER2 expression, Tiam1 expression was
inverselyrelated to the HER2 expression. Multivariate sur-
vival analysis showed that Tiam1 expression level was a
significantly and independent prognostic factor along with
tumor stage in breast cancer, but not HER2 expression. It
might be known that, Tiam1 could be involved in the
tumorigenesis and tumor growth through different signal
transduction pathway, such as Tiam1-Rac signaling path-
way [15]. Wang et al. [28] reported that HER2 can activate
Rac1 by activating PI3K/Akt pathway. Consequently, the
molecular mechanism of Tiam1-regulation in breast can-
cer needs the further study to clarify.
As many studies demonstrated that, lymph node me-
tastasis, as well as Her-2 and Ki-67 expression was the
independent prognostic factors in breast cancer. Chen et
al. [29] reported that Ki-67 expression was associated
with lymph node metastasis frequently in all types of
breast cancer. However, our contingency table analysis
showed that Tiam1 expression did not correlate with
lymph node metastasis, but associated with Ki-67 ex-
pression. Yang et al. [19] found that expression of Tiam1
in HCC tissues was associated with tumor stage, high
AFP level and intrahepatic metastasis. Consistently, our
study showed that up-regulation of Tiam1 was corre-
lated with tumor stage in breast cancer. These results in-
dicated that up-regulation of Tiam1 expression might
promote the malignant potential of breast cancer. Thus,
Tiam1 may act as a valuable molecular marker for breast
cancer invasion, and play a key role in prognosis
prediction.
In regards to survival, we found that high expression
of Tiam1 protein was strongly associated with molecular
subtype and tumor stage, which were important features
associated with poor prognosis in breast cancer. Also,
we found that Tiam1 expression was strongly related to
Fig. 3 Relationship between Tiam1 expression and clinicopathological significance of breast cancer. The expression level of Tiam1 protein was
significantly related to tumor stage (P = 0.002), Her2 expression (P = 0.046) and Ki-67 expression (P = 0.008)
Fig. 4 Kaplan-Meier analysis of breast cancer patient survival rates in relation to Tiam1 protein expression. Disease-free survival (a) and 10-year
overall survival (b) rates of patients with high (red, n = 65) and low (green, n = 88) Tiam1 expression
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Fig. 5 Kaplan-Meier analyses of survival rates in patients with high- or low-level Tiam1 expression and with early- or late-stage breast cancer. DFS
(a) and OS (b) rates were assessed in patients with early-stage breast cancer concomitant with either high- (green, n = 26) or low-level (black, n = 58)
Tiam1 expression. DFS (c) and OS (d) rates were also assessed in patients with late-stage breast cancer concomitant with high- (blue,
n = 39) or low-level (red, n = 30) Tiam1 expression
Table 3 Univariate and Multivariate survival analyses (Cox regression model) of various factors in 153 patients with breast cancer
Factors DFS Hazard ratio (95 % CI) P value OS Hazard ratio (95 % CI) P value
Univariate analyses
Age 1.172(0.851–1.616) 0.331 1.162(0.844–1.601) 0.358
Menopausal status 1.015(0.831–1.239) 0.885 1.016(0.831–1.242) 0.878
Molecular type 1.373(0.995–1.896) 0.054 1.385(1.004–1.912) 0.047*
Tumor stage 0.685(0.590–0.796) 0.000** 0.694(0.599–0.805) 0.000**
LN metastasis 1.287(0.927–1.786) 0.131 1.335(0.961–1.855) 0.085
ER 1.171(0.848–1.616) 0.338 1.163(0.843–1.605) 0.359
PR 1.016(0.736–1.404) 0.922 1.048(0.760–1.446) 0.774
Her2 1.646(1.186–2.285) 0.003** 1.740(1.245–2.431) 0.001**
Ki-67 1.058(0.765–1.4622) 0.734 1.075(0.777–1.485) 0.663
Tiam1 1.781(1.276–2.487) 0.001** 1.671(1.204–2.320) 0.002**
Multivariate analyses
Tiam1 1.470(1.056–2.047) 0.022* 1.549(1.112–2.157) 0.010*
Molecular type 1.340(0.963–1.865) 0.082
Tumor stage 0.567(0.413–0.778) 0.000** 0.585(0.425–0.805) 0.001**
Her2 0.585(0.290–1.179) 0.134 0.617(0.298–1.276) 0.617
95 % CI 95 % confidence interval * p < 0.05, ** p < 0.01
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survival rates in early- and late-stage tumors, and sur-
vival rates were significantly higher in patients with
low Tiam1 expression than those with high Tiam1 ex-
pression. Consistent with these results, Yang et al. [9]
reported that, in hepatocellular cancers (HCCs),
Tiam1 expression was associated with shorter
recurrence-free survival and disease-specific survival.
In addition, Ding et al. [30] demonstrated that Tiam1
overexpression acts as an independent prognosis fac-
tor for HCC patients. Similarly, Hsueh et al. [31] re-
ported that Tiam1 expression was associated with the
clinicopathologic features and prognostic significance
in patients with papillary thyroid carcinoma. Thus, in-
creased expression of Tiam1 might promote the ma-
lignant potential of breast cancer, and Tiam1
overexpression might be used as a potential predictive
biomarker of poor prognosis in patients with breast
cancer.
Currently, many studies have reported that Tiam1
participates in several signaling pathways in tumor
cells, and plays important roles in cancer progression,
metastasis and invasion. Malliri et al. [32] reported
that Tiam1 was essential for the formation, as well as
the maintenance, of cadherin-based adhesions. Walch
et al. [33] reported that Tiam1 was a regulator of E-
cadherin-mediated cell adhesion, and indicated that in
combination with E-cadherin expression, Tiam1 acts
as a useful marker in gastric carcinogenesis. Hordijk
et al. [34] and Liu et al. [35] reported that Tiam1
regulates the formation of cell-cell adhesion, induces
Mesenchymal-Epithelial transition (MET), and thus
inhibits epithelial cell migration. In part, this may be
due to Tiam1’s ability to regulate E-cadherin expres-
sion, since loss of E-cadherin expression is considered
to be a signature event in Epithelial-Mesenchymal
transition (EMT), which is the reverse process of
MET and has a pivotal role in cancer invasion and
metastasis. Specifically, EMT is a process by which
epithelial cells lose cell-cell adhesion, and gain migra-
tory and invasive properties to become mesenchymal-
like cells. Therefore, these data suggest that altered
Tiam1 expression patterns might regulate a certain
signaling pathway to play a key role in cancer inva-
sion and metastasis. Further investigation is required
to determine the role of Tiam1 in breast cancer
progression.
Conclusions
In conclusion, Tiam1 expression is frequently up-
regulated in breast cancer, and Tiam1 overexpression
correlated with clinicopathological parameters. Tiam1
may serve as a useful prognostic biomarker and a poten-
tial therapeutic target for patients with breast cancer.
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